Cyclopenta[cd]
pyrene (
CPP) was a potent tumorigen when tested over a 5-fold dose range in the newborn mouse assay. A 20-fold increase in lung
tumor multiplicity and a nearly 8-fold increase in
tumor incidence was observed at the lowest total dose tested (1.55 mumol) with the dose-response relationship indicating a saturation of
tumor multiplicity at approximately 7
tumors/animal. No liver nodules or lymphatic system
tumors were noted. Analysis of dose-response data for
benzo[a]-pyrene (BaP) and
6-nitrochrysene (6-NC) showed that
tumor multiplicity for BaP also saturated at approximately 7
tumors/animal, whereas no similar saturation was found for 6-NC at up to 40
tumors/animal. Progression of lung
adenomas to
adenocarcinomas, as measured by the incidence of mice bearing malignant
tumors, was essentially a linear function of dose. To facilitate comparison and maximize quantitative data obtainable from the newborn mouse assay-parameters were defined for
tumor incidence (ED50),
tumor multiplicity (TM1.0) and
tumor malignancy (
malignancy index). Values for the ED50 and TM1.0 were similar for the same compound and a tumorigenic potency series of 6-NC greater than BaP greater than
CPP was obtained corresponding to a ratio of approximately 1:10-25:76.5-135, respectively. The
malignancy index, however, indicated increased
adenocarcinoma induction in the order
CPP greater than 6-NC greater than BaP as expressed by the ratio 1:1.4:8.3, respectively.